Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical ...
BofA has initiated coverage of Candel Therapeutics (CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. Read more here.
A heartfelt message shared on social media with permission from his family encourages those who can to contribute towards his medical expenses and support.
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...
retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...
There are self-care strategies that may aid in helping to prevent prostate cancer, the second most common cause of cancer-related death in men. Located below the bladder, the prostate is the gland ...